Dr. Kaveh Vejdani, Co-founder and Chief Medical and Technology Officer at Darmiyan, discusses BrainSee, the first FDA-approved AI medical software designed to evaluate cognitive prognosis in patients with mild cognitive impairment (MCI).
With a background in nuclear medicine and expertise in medical image processing and machine learning, Dr. Vejdani's work reflects his commitment to innovation in healthcare. BrainSee aims to solve the global crisis of dementia through early detection and accurate prognosis of MCI, potentially improving patients' brain health journeys and treatment outcomes.
The BrainSee technology combines MRI data with cognitive assessments to predict the likelihood of progression to Alzheimer's disease, providing valuable support to both patients and healthcare providers in managing MCI.
00:00 Meet Dr. Kaveh Vejdani: An Innovator at the Intersection of AI and Healthcare
01:25 The Genesis of a Medical Visionary: From Passion to Innovation
02:30 Understanding Mild Cognitive Impairment (MCI) with Dr. Vejdani
07:10 The Revolutionary Brain See: A Leap Forward in Cognitive Health
11:22 Navigating the Complexities of MCI Diagnosis and Management
22:00 The Future of MCI Detection: Brain See's Impact and Potential
27:44 Final Thoughts: Empowering MCI Understanding and Management
Resources:
Learn more about Darmyian on their website.
Explore Brain See and its recent FDA approval!
Read the 2024 Alzheimer’s Disease Facts & Figures report.
--- Support this podcast: https://podcasters.spotify.com/pod/show/virtualbrainhealthcenter/support
Chief Medical & Technology Officer
Dr. Kaveh Vejdani is a nuclear medicine physician specialized in PET/CT and PET/MR from Stanford University and NYU Langone Medical Center. He is also a computer programmer and expert in medical image processing and machine learning. In Darmiyan, as the chief medical and technology officer, he leads the development of the company’s core virtual microscope technology that extracts novel biomarkers of neurodegeneration from standard clinical brain MR images.
He has actively led the development, testing and validation of the core algorithm behind Darmiyan's first clinical product, BrainSee, as well the design, development, testing, FDA-breakthrough designation, clinical validation, and FDA De Novo approval of the BrainSee platform, the first prognostic AI to help clinicians in the evaluation of patients who struggle with memory loss and are diagnosed with mild cognitive impairment (MCI).
Dr. Vejdani received his MD degree in 2003 and performed postdoctoral research at UCSF, followed by residency training in nuclear medicine at Saint Louis University. His professional experience ranges from tissue engineering (stem cells and biomaterials) to radiology, molecular imaging, machine learning and AI.
In his free time, if there is any, Kaveh enjoys hang gliding, playing violin and chess, and making telescopes and iPhone apps.